<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02012309</url>
  </required_header>
  <id_info>
    <org_study_id>13-2405</org_study_id>
    <secondary_id>R01AI108479</secondary_id>
    <nct_id>NCT02012309</nct_id>
  </id_info>
  <brief_title>Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses</brief_title>
  <official_title>Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human Immunodeficiency Virus (HIV) infection is complicated by high rates of infections and&#xD;
      cancers which are often the cause of death rather than the HIV/acquired immune deficiency&#xD;
      syndrome (AIDS) virus itself. Treatment of HIV with antiretroviral medications has decreased&#xD;
      the frequency of many complications by over 90%, but bacterial pneumonia remains extremely&#xD;
      high. Current vaccines are not very effective in preventing these infections in patients with&#xD;
      HIV infection. The investigators are studying the cells (B cells) that make antibodies to&#xD;
      fight infection by binding to and killing bacteria. The goal is to understand how HIV impairs&#xD;
      the ability of B cells to make antibodies in sufficient quantity and of sufficient quality to&#xD;
      protect patients with HIV to learn how to enhance protection against these infections. The&#xD;
      investigators also seek to understand the role of the bacteria (specifically Streptococcus&#xD;
      pneumoniae) that normally live in the nose and throat in the development of pneumonia and&#xD;
      other infections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>B and T cell subsets</measure>
    <time_frame>Weeks -12, 0, 1, 8, 9, 16</time_frame>
    <description>Activation and subset distribution of B and T cell subsets and cluster of differentiation positive (CD4+) T cells and T follicular helper (TFH) cells on days 0 and 7 after stimulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total IgG, IgM and IgA</measure>
    <time_frame>Weeks -12, 0, 1, 8, 9, 16</time_frame>
    <description>Total immunoglobulin G (IgG), immunoglobulin M (IgM) and immunoglobulin A (IgA) produced from culture of peripheral blood mononuclear cells (PBMC) stimulated in triplicate with B cell stimuli on day 7 by enzyme-linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody-secreting cells</measure>
    <time_frame>Weeks 0, 1, 8, 9</time_frame>
    <description>Total IgG, IgM and IgA antibody-secreting cells (ASC) enumerated by enzyme-linked immunospot (ELISPOT) on day 0 and day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AID and BCL-6 production</measure>
    <time_frame>Weeks -12, 0, 1, 8, 9, 16</time_frame>
    <description>RNA extraction for activation-induced cytidine deaminase (AID) and B cell lymphoma protein 6 (BCL6) expression and mutation from stimulated B cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>S.pneumoniae colonization and nasopharyngeal microbiome</measure>
    <time_frame>Weeks -12, 0, 8, 16</time_frame>
    <description>Prevalence of nasopharyngeal S. pneumoniae determined by quantitative polymerase chain reaction(Q-PCR) and 16S ribosomal RNA (rRNA) sequencing, related microbiota (commensal bacteria) and correlation between colonization and levels of pneumococcal capsule-specific IgG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S.pneumoniae urine antigen positivity</measure>
    <time_frame>Week -12</time_frame>
    <description>S. pneumoniae urine antigen positivity in relation to colonization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV</condition>
  <condition>Pneumococcal Infections</condition>
  <condition>Pneumococcal Vaccines</condition>
  <arm_group>
    <arm_group_label>HIV-seronegative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-seronegative subjects will receive Prevnar (PCV-13) at week 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-infected</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected subjects will receive Prevnar (PCV-13) at week 0, and Pneumovax (PPSV-23) at week 8 per Advisory Committee on Immunization Practices (ACIP) guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV-13</intervention_name>
    <arm_group_label>HIV-infected</arm_group_label>
    <arm_group_label>HIV-seronegative</arm_group_label>
    <other_name>Prevnar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PPSV-23</intervention_name>
    <arm_group_label>HIV-infected</arm_group_label>
    <other_name>Pneumovax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For HIV-infected subjects:&#xD;
&#xD;
          -  adults aged 18-55 years&#xD;
&#xD;
          -  &gt;200 CD4+ T-cells/microliter&#xD;
&#xD;
          -  no antiretroviral therapy (at the time of nasal swab/week 0)&#xD;
&#xD;
          -  receiving antiretroviral therapy for &gt;6 weeks (at the time of vaccination/week 12)&#xD;
&#xD;
        For HIV-seronegative controls:&#xD;
&#xD;
          -  adults aged 18-55 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For all subjects:&#xD;
&#xD;
          -  age &lt;18 or &gt;55 years&#xD;
&#xD;
          -  history of prior pneumococcal vaccination&#xD;
&#xD;
          -  immunosuppressive therapy, defined as: prednisone &gt;15mg/day currently or &gt;14 days in&#xD;
             the past 3 months, cytotoxic agents, anti-metabolites, cyclosporine, anti-tumor&#xD;
             necrosis factor, B cell monoclonal antibodies&#xD;
&#xD;
          -  current or chronic pulmonary infection (bacterial, fungal, mycobacterial), pneumonia,&#xD;
             or rhinosinusitis within 2 months&#xD;
&#xD;
          -  chronic lung disease&#xD;
&#xD;
          -  renal insufficiency, defined as serum creatinine &gt;1.6&#xD;
&#xD;
          -  active liver disease, including hepatitis C virus infection&#xD;
&#xD;
          -  history of splenectomy&#xD;
&#xD;
          -  history of antibacterial therapy within 3 months of nasal swab (week 0)&#xD;
&#xD;
          -  current alcohol abuse&#xD;
&#xD;
          -  chronic heart disease&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  current cigarette smoking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward N Janoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado-Denver, Denver VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado-Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health and Hospitals</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver VA Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2013</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Streptococcus pneumoniae infection</keyword>
  <keyword>Streptococcus pneumoniae colonization</keyword>
  <keyword>Pneumococcal vaccines</keyword>
  <keyword>Prevnar</keyword>
  <keyword>Pneumovax</keyword>
  <keyword>Nasopharyngeal microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

